SELECT
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is SELECT?
SELECT ran semaglutide 2.4 mg against placebo in an enrolled population of 17,604 people who were overweight or obese and already had cardiovascular disease, none of them diabetic (Lincoff et al., NEJM 2023).
Major adverse cardiovascular events fell 20% (HR 0.80, 95% CI 0.72–0.90). That result is the reason the drug now gets argued about as cardiac prevention instead of cosmetics.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where SELECT comes up on this site
On GLP Watchdog, SELECT comes up in 2 research articles and 1 tool.
Research that discusses it
Tools that use it
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers